Skip to main
SGMT
SGMT logo

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences Inc. possesses a promising outlook based on the positive safety profile of its drug candidate, denifanstat, evidenced by prior Phase II studies, which enhances its potential as a suitable option for combination therapies. The preclinical studies have demonstrated denifanstat's additive efficacy in both reducing liver fat and improving liver fibrosis when combined with resmetirom, highlighting the drug's therapeutic potential in treating diseases associated with dysfunctional lipid metabolism. These factors contribute to a belief in the company's ability to develop innovative therapies for conditions such as nonalcoholic steatohepatitis (NASH), underscoring its commitment to advancing effective treatments in the biopharmaceutical sector.

Bears say

Sagimet Biosciences Inc. faces a negative outlook primarily due to high turnover in key regulatory roles such as CEO and CMO, which could create instability and adversely affect share performance. Additionally, any emerging efficacy or safety concerns regarding its drug candidate, denifanstat, during clinical development may further diminish investor confidence and negatively influence the stock’s market performance. These factors contribute to a generally precarious financial standing and uncertainty surrounding the company's future prospects in developing therapeutic solutions.

SGMT has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Strong Buy based on their latest research and market trends.

According to 7 analysts, SGMT has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.